REFERENCES
1. Van Kranenburg M, Magro M, Thiele H, et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7:930-9.
2. Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol. 2019;114:45.
3. Chang C, Huang W, Cai R, Mo L, Wu Q, Su Q. Research progress of regulatory cell death in coronary microembolization. Int J Med Sci. 2025;22:132-9.
4. Gao X, Wu Q, Kiriazis H, et al. Microvascular leakage in acute myocardial infarction: characterization by histology, biochemistry, and magnetic resonance imaging. Am J Physiol Heart Circ Physiol. 2017;312:H1068-75.
5. Zhao B, Ruze A, Zhao L, et al. The role and mechanisms of microvascular damage in the ischemic myocardium. Cell Mol Life Sci. 2023;80:341.
6. Durante A, Mazzapicchi A, Baiardo Redaelli M. Systemic and cardiac microvascular dysfunction in hypertension. Int J Mol Sci. 2024;25:13294.
7. Varughese GI, Tomson J, Lip GYH. Type 2 diabetes mellitus: a cardiovascular perspective: type 2 diabetes mellitus. Int J Clin Pract. 2005;59:798-816.
8. Stratmann B, Tschoepe D. Atherogenesis and atherothrombosis - focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 2009;23:291-303.
9. Koller A, Szenasi A, Dornyei G, Kovacs N, Lelbach A, Kovacs I. Coronary microvascular and cardiac dysfunction due to homocysteine pathometabolism; a complex therapeutic design. Curr Pharm Des. 2018;24:2911-20.
10. Hausenloy DJ, Chilian W, Crea F, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res. 2019;115:1143-55.
11. Porto I, Biasucci LM, De Maria GL, et al. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J. 2012;33:2928-38.
12. Witkowski M, Witkowski M, Friebel J, et al. Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. Cardiovasc Res. 2022;118:2367-84.
13. Yang T, Wu X, Wang X. HMGB1 regulates autophagy via TLR4/NF-κB signaling pathway in myocardial injury induced by coronary microembolization. Eur J Med Res. 2025;30:943.
14. Van Den Berg J, Haslbauer JD, Stalder AK, et al. Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies. Res Pract Thromb Haemost. 2023;7:100182.
15. Liu A, Ghazizadeh M, Onouchi Z, Asano G. Ultrastructural characteristics of myocardial and coronary microvascular lesions in Kawasaki disease. Microvasc Res. 1999;58:10-27.
16. Patra PK, Banday AZ, Das RR, Manohari S, Jindal AK, Singh S. Long-term vascular dysfunction in Kawasaki disease: systematic review and meta-analyses. Cardiol Young. 2022;33:1614-26.
17. Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020;25:471-8.
18. Tahir S, Wagner AH, Dietzel S, et al. Endothelial CD40 mediates microvascular von Willebrand factor-dependent platelet adhesion inducing inflammatory venothrombosis in ADAMTS13 Knockout mice. Thromb Haemost. 2020;120:466-76.
19. Huang J, Li X, Shi X, et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12:26.
20. Rumbaut RE, Bellera RV, Randhawa JK, et al. Endotoxin enhances microvascular thrombosis in mouse cremaster venules via a TLR4-dependent, neutrophil-independent mechanism. Am J Physiol Heart Circ Physiol. 2006;290:H1671-9.
21. Maiocchi S, Alwis I, Wu M, Yuan Y, Jackson S. Thromboinflammatory functions of platelets in ischemia-reperfusion injury and its dysregulation in diabetes. Semin Thromb Hemost. 2018;44:102-13.
22. Bei J, Liu C, Peng S, et al. Staphylococcal SSL5-induced platelet microparticles provoke proinflammatory responses via the CD40/TRAF6/NFKB signalling pathway in monocytes. Thromb Haemost. 2018;115:632-45.
23. Siljander P, Carpen O, Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood. 1996;87:4651-63.
24. Aleman M, Gardiner C, Harrison P, Wolberg A. Differential contributions of monocyte‐ and platelet‐derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost. 2011;9:2251-61.
25. Mcfadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127:571-87.
26. Sun C, Feng S, Cao Z, et al. Up-regulated expression of matrix metalloproteinases in endothelial cells mediates platelet microvesicle-induced angiogenesis. Cell Physiol Biochem. 2017;41:2319-32.
27. Juchem G, Weiss DR, Knott M, et al. Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models. Am J Physiol Heart Circ Physiol. 2012;302:H567-81.
28. Gao X, Su Y, Moore S, et al. Relaxin mitigates microvascular damage and inflammation following cardiac ischemia-reperfusion. Basic Res Cardiol. 2019;114:30.
29. Khan AO, Reyat JS, Hill H, et al. Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. Cardiovasc Res. 2022;118:3085-96.
30. Lapii G, Bakarev M, Lushnikova E. Morphological and immunohistochemical characteristics of the heart of patients with COVID-19. Rus J Arch Pathol. 2026;88:44.
31. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med. 2003;3:147-62.
32. Wang Y, Gao H, Shi C, et al. Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα. Nat Commun. 2017;8:15559.
33. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2002;9:61-7.
34. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111:633-42.
35. Xu Y, Ouyang X, Yan L, et al. Sin1 (stress-activated protein kinase-interacting protein) regulates ischemia-induced microthrombosis through integrin αIIbβ3-mediated outside-in signaling and hypoxia responses in platelets. Arterioscler Thromb Vasc Biol. 2018;38:2793-805.
36. Ding Y, Liu K, Wang Y, et al. Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes. J Huazhong Univ Sci Technol. 2010;30:575-81.
37. Fu L, Mackeigan DT, Gong Q, et al. Thymic stromal lymphopoietin induces platelet mitophagy and promotes thrombosis in Kawasaki disease. Br J Haematol. 2022;200:776-91.
38. Hamad MA, Krauel K, Schanze N, et al. Platelet subtypes in inflammatory settings. Front Cardiovasc Med. 2022;9:823549.
39. Kaiser R, Nicolai L. Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease. Nat Rev Cardiol. 2026;23:473-85.
40. Bongiovanni D, Santamaria G, Klug M, et al. Transcriptome analysis of reticulated platelets reveals a prothrombotic profile. Thromb Haemost. 2019;119:1795-806.
41. Mcbane RD, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis. 2013;37:148-54.
42. Bodrova VV, Shustova ON, Golubeva NV, et al. Platelet function, platelet size and content of reticulated platelets: interactions in patients receiving dual antiplatelet therapy. Cells. 2024;13:1712.
43. Gumiężna K, Baruś P, Sygitowicz G, et al. Prognostic implications of immature platelet fraction at 5-year follow-up among ACS patients treated with dual antiplatelet therapy. J Cardiovasc Pharmacol Ther. 2024;29:10742484231202864.
44. Kirmes K, Han J, Klug M, et al. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Eur Heart J. 2025;46:4901-17.
45. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133:906-18.
46. Polytarchou K, Varvarousis D, Manolis AS. Cardiovascular disease in antiphospholipid syndrome. Curr Vasc Pharmacol. 2020;18:538-48.
47. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2013;10:9-17.
48. Deng Y, Lin X, Wei J, et al. Endothelial cell iron overload and ferroptosis mediate thrombosis and inflammation through the miR-32-5p/neurofibromin 2 pathway. Eur J Med Res. 2025;30:463.
49. Karbakhsh Ravari F, Ghasemi Gorji M, Rafiei A. From iron-driven cell death to clot formation: the emerging role of ferroptosis in thrombogenesis. Biomed Pharmacother. 2025;189:118328.
50. Ge L, Zhou X, Ji W, et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J Physiol Heart Circ Physiol. 2015;308:H500-9.
51. Nicolai L, Kaiser R, Stark K. Thromboinflammation in long COVID-the elusive key to postinfection sequelae? J Thromb Haemost. 2023;21:2020-31.
52. Restrepo MI, Marin-Corral J, Rodriguez JJ, Restrepo V, Cavallazzi R. Cardiovascular complications in coronavirus disease 2019-pathogenesis and management. Semin Respir Crit Care Med. 2023;44:021-34.
53. Maiese A, Frati P, Del Duca F, et al. Myocardial pathology in COVID-19-associated cardiac injury: a systematic review. Diagnostics. 2021;11:1647.
54. Xanthopoulos A, Bourazana A, Giamouzis G, et al. COVID-19 and the heart. World J Clin Cases. 2022;10:9970-84.
55. Martinod K, Claessen A, Martens C, et al. NET burden in left atrial blood is associated with biomarkers of thrombosis and cardiac injury in patients with enlarged left atria. Clin Res Cardiol. 2024;114:112-25.
56. Chang JC, Hawley HB. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to venous combined micro-macrothrombosis. Medicina. 2021;57:1163.
57. Hoofnagle MH, Hess A, Nalugo M, et al. Defects in vein valve PROX1/FOXC2 antithrombotic pathway in endothelial cells drive the hypercoagulable state induced by trauma and critical illness. J Trauma Acute Care Surg. 2023;95:197-204.
58. Liu X, Hu Y, Yu X, et al. Differential contributions of the C5b-9 and C5a/C5aR pathways to microvascular and macrovascular thrombosis in complement-mediated thrombotic microangiopathy patients. Clin Immunol. 2024;259:109871.
59. Kostin S, Giannakopoulos T, Richter M, et al. Coronary microthrombi in the failing human heart: the role of von Willebrand factor and PECAM-1. Mol Cell Biochem. 2024;479:3437-46.
60. Khan GA, Huwaikem M, Chowdhury K, Albugami HF, Ghosh A. The role of sterile inflammation in thrombosis: consequences for cardiovascular disease and COVID‐19. Mediators Inflamm. 2025;2025:8054886.
61. Wu H, Li R, Pei L, et al. Emerging role of high mobility group box-1 in thrombosis-related diseases. Cell Physiol Biochem. 2018;47:1319-37.
62. Yuan Y, Li B, Peng W, Xu Z. Protective effect of glycyrrhizin on coronary microembolization‐induced myocardial dysfunction in rats. Pharmacol Res Perspec. 2021;9:e00714.
63. Zhao X, Han J, Zhou L, et al. High mobility group box 1 derived mainly from platelet microparticles exacerbates microvascular obstruction in no reflow. Thromb Res. 2023;222:49-62.
64. Zhang Z, Qin S, Wang Y, Liang H, Wang R, Li F. L-ascorbic acid could ameliorate the damage of myocardial microvascular endothelial cell caused by hypoxia-reoxygenation via targeting HMGB1. J Bioenerg Biomembr. 2023;55:115-22.
65. Chen Q, Bei J, Liu C, et al. HMGB1 induces secretion of matrix vesicles by macrophages to enhance ectopic mineralization. PLoS ONE. 2016;11:e0156686.
66. Su Q, Qin J, Huang Y, et al. USP16 S-nitrosylation aggravates coronary microembolization-induced myocardial injury via repressing KDM1A-mediated glutathione homeostasis. Nat Commun. 2025;17:255.
67. Durante A, Laricchia A, Benedetti G, et al. Identification of high-risk patients after ST-segment-elevation myocardial infarction: comparison between angiographic and magnetic resonance parameters. Circ Cardiovasc Imaging. 2017;10:e005841.
68. Bulluck H, Carberry J, Carrick D, et al. A noncontrast CMR risk score for long-term risk stratification in reperfused ST-segment elevation myocardial infarction. JACC Cardiovasc Imaging. 2022;15:431-40.
69. Cicala S, Galderisi M, Grieco M, et al. Transthoracic echo-doppler assessment of coronary microvascular function late after Kawasaki disease. Pediatr Cardiol. 2007;29:321-7.
70. Arora K, Guleria S, Jindal AK, Rawat A, Singh S. Platelets in Kawasaki disease: is this only a numbers game or something beyond? Genes Dis. 2020;7:62-6.
71. Noval Rivas M, Kocatürk B, Franklin BS, Arditi M. Platelets in Kawasaki disease: mediators of vascular inflammation. Nat Rev Rheumatol. 2024;20:459-72.
72. Bekhet M, Marks-Hultström A, Korkut GG, et al. Renal microthrombosis and thrombomodulin deficiency in COVID-19-associated acute kidney injury. BMC Nephrol. 2026;27:146.
73. Mejía-Romero R, García-Carrasco M, Galarza-Maldonado C, et al. Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients. Clin Rheumatol. 2007;27:891-7.
74. Pons I, Jeréz A, Espinosa G, et al. Cardiac involvement in the catastrophic antiphospholipid syndrome (CAPS): lessons from the “CAPS registry”. Semin Arthritis Rheum. 2024;66:152439.
75. Yue W, Xu Y, Weng X, et al. Systolic pressure overload caused pulmonary oxidative stress, vessel remodeling and severe microvascular thrombosis in CD40 knockout mice through promoting platelet aggregation. Redox Biol. 2026;92:104122.
76. Nomura S. Dynamic role of microparticles in type 2 diabetes mellitus. Curr Diabetes Rev. 2009;5:245-51.
77. Morel O, Hugel B, Jesel L, et al. [Procoagulant membranous microparticles and atherothrombotic complications in diabetics]. Arch Mal Coeur Vaiss. 2004;97:1006-12.
78. Qi K, Li X, Geng Y, et al. Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-α pathway. PLoS ONE. 2018;13:e0198403.
79. Du M, Hui H, Sun S, et al. Association between coronary thrombus composition and microvascular obstruction following percutaneous coronary intervention in patients with acute myocardial infarction: a proof-of-concept study. Medicine. 2025;104:e44639.
80. Jacovina AT, Deora AB, Ling Q, et al. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Investig. 2009;119:3384-94.
81. Liu X, Liu H, Wang N, et al. The interactive toxic effect of homocysteine and copper on cardiac microvascular endothelial cells during ischemia-reperfusion injury. Chem Biol Interact. 2025;408:111387.
82. Rao J, Ding C, Huang X, et al. Mechanistic insights into homocysteine-induced coronary microcirculatory dysfunction post-MI: the pivotal role of LncMEG3/miR-223/NLRP3 signaling axis. Cell Signal. 2025;136:112164.
83. Wang Z, Wang Y, Cheng Y, et al. Decoding post-myocardial infarction coronary microvascular dysfunction: the SP1-driven STAT3/KCa3.1/eNOS protective mechanism. Cytojournal. 2025;22:66.
84. Padró T, Vilahur G, Badimon L. Dyslipidemias and microcirculation. Curr Pharm Des. 2018;24:2921-6.
85. Berger M, Naseem KM. Oxidised low-density lipoprotein-induced platelet hyperactivity -receptors and signalling mechanisms. Int J Mol Sci. 2022;23:9199.
86. Mansouri P, Golchin Vafa R. The role of lipoprotein(a) in coronary microvascular dysfunction: mechanistic pathways, clinical evidence, and therapeutic perspectives. Life Sci. 2026;396:124371.
87. Ridger VC, Boulanger CM, Angelillo-Scherrer A, et al. Microvesicles in vascular homeostasis and diseases: position paper of the european society of cardiology (ESC) working group on atherosclerosis and vascular biology. Thromb Haemost. 2017;117:1296-316.
88. Gkaliagkousi E, Gavriilaki E, Yiannaki E, et al. Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation. J Thromb Thrombolysis. 2020;51:1138-43.
89. Sun C, Zhao W, Chen Y, Hu H. Higher plasma concentrations of platelet microparticles in patients with acute coronary syndrome: a systematic review and meta-analysis. Can J Cardiol. 2016;32:1325.e1-10.
90. Bao H, Chen YX, Huang K, et al. Platelet‐derived microparticles promote endothelial cell proliferation in hypertensionviamiR‐142-3p. FASEB J. 2018;32:3912-23.
91. Nunki N, Hernaningsih Y, Wardhani P, et al. Platelet and monocyte microvesicles as potential biomarkers of COVID-19 severity: a cross-sectional analysis. Ann Lab Med. 2024;44:392-400.
92. Lacroix R, Robert S, Poncelet P, Kasthuri R, Key N, Dignat-George F. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost. 2010;8:2571-4.
93. Wang X, Yu H, Zhang Y, et al. Serial changes of mean platelet volume in relation to Killip Class in patients with acute myocardial infarction and primary percutaneous coronary intervention. Thromb Res. 2015;135:652-8.
94. Gao X, Moore X, Liu Y, et al. Splenic release of platelets contributes to increased circulating platelet size and inflammation after myocardial infarction. Clin Sci. 2016;130:1089-104.
95. Qiu Y, Luo J, Luo F, et al. Prognostic value of the PDW/HDL-C ratio in patients with chest pain symptoms and coronary artery calcification. Front Cardiovasc Med. 2022;9:824955.
96. Tscharre M, Vogel B, Tentzeris I, et al. Prognostic impact of soluble P-selectin on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention. Thromb Haemost. 2018;119:340-7.
97. Illési Á, Fejes Z, Pócsi M, et al. Technically challenging percutaneous interventions of chronic total occlusions are associated with enhanced platelet activation. J Clin Med. 2023;12:6829.
98. Nishikawa M, Kanno H, Zhou Y, et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun. 2021;12:7135.
99. Liu Y, Gao X, Fang L, et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31:834-41.
100. Beitzen-Heineke A, Muller MA, Xia Y, et al. A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk. JCI Insight. 2025;10:e195824.
101. Gurbel PA, Galbut B, Bliden KP, et al. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration - therapeutic yield on platelets (the EARLY platelet substudy). J Thromb Thrombolysis. 2002;14:213-9.
102. Barillà F, Cammisotto V, Bartimoccia S, et al. Toll-like receptor 4 activation in platelets from myocardial infarction patients. Thromb Res. 2022;209:33-40.
103. Lacroix R, Judicone C, Mooberry M, et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost. 2013;11:1190-3.
104. Schnorbus B, Jurk K, Lackner KJ, Welk C, Münzel T, Gori T. Effects of clopidogrel, prasugrel and ticagrelor on microvascular function and platelet reactivity in patients with acute coronary syndrome undergoing coronary artery stenting. A randomized, blinded, parallel group trial. Front Cardiovasc Med. 2021;8:780605.
105. Eitel I, Saraei R, Jurczyk D, et al. Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial. Eur Heart J. 2024;45:5058-67.
106. Du X, Shan L, Gao X, et al. Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. Thromb Haemost. 2017;105:356-64.
107. Khattak S, Townend JN, Thomas MR. Impact of antiplatelet therapy on microvascular thrombosis during ST-elevation myocardial infarction. Front Mol Biosci. 2024;11:1287553.
108. Tang S, Ye J, Li R, et al. Formononetin attenuates myocardial ischemia/reperfusion injury by regulating neutrophil extracellular traps formation and platelet activation via platelet CD36. Phytomedicine. 2025;141:156736.
109. Broch K, Anstensrud AK, Woxholt S, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845-55.
110. Woxholt S, Ueland T, Aukrust P, et al. Effect of tocilizumab on endothelial and platelet-derived CXC-chemokines and their association with inflammation and myocardial injury in STEMI patients undergoing primary PCI. Int J Cardiol. 2025;418:132613.
111. Kindberg KM, Broch K, Andersen GØ, et al. Neutrophil extracellular traps in ST-segment elevation myocardial infarction: reduced by tocilizumab and associated with infarct size. JACC Adv. 2024;3:101193.
112. Huse C, Murphy SL, Yang K, et al. The effects of interleukin-6-receptor inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial. eBioMedicine. 2025;121:105960.
113. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-32.
114. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393:2409-20.
115. Cameron-Vendrig A, Reheman A, Siraj MA, et al. Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes. 2016;65:1714-23.
116. Steven S, Jurk K, Kopp M, et al. Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. Br J Pharmacol. 2016;174:1620-32.
117. García-Vega D, Sánchez-López D, Rodríguez-Carnero G, et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc Diabetol. 2024;23:1.
118. Van Gelderen CEM, Bijlsma JA, Van Dokkum W, Savelkoull TJF. Glycyrrhizic acid: the assessment of a no effect level. Hum Exp Toxicol. 2000;19:434-9.
119. Mendes-Silva W, Assafim M, Ruta B, Monteiro RQ, Guimarães JA, Zingali RB. Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor. Thromb Res. 2003;112:93-8.
120. Bani D, Bigazzi M, Masini E, et al. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Lab Invest. 1995;73:709-16.
121. Bani D, Maurizi M, Bigazzi M. Original article: relaxin reduces the number of circulating platelets and depresses platelet release from megakaryocytes: studies in rats. Platelets. 2009;6:330-5.
122. Zavadovsky KV, Ryabov VV, Vyshlov EV, et al. Intra-myocardial hemorrhage and cardiac microvascular injury in ischemia/reperfusion. A systematic review of current evidences. Curr Probl Cardiol. 2025;50:102918.
123. Penaloza Arias LC, Huynh DN, Babity S, Marleau S, Brambilla D. Optimization of a liposomal DNase I formulation with an extended circulating half-life. Mol Pharm. 2022;19:1906-16.
124. Nakazawa D, Kumar SV, Marschner J, et al. Histones and neutrophil extracellular traps enhance tubular necrosis and remote organ injury in ischemic AKI. J Am Soc Nephrol. 2017;28:1753-68.
125. Chen S, Lin J, Huang J, Deng L, Zhang Y. The S100A8/A9-NETosis feedback loop in sepsis: potential mechanisms, immune crosstalk, and therapeutic targeting. Front Immunol. 2026;17:1790788.
126. Cantin AM. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice. Am J Respir Crit Care Med. 1998;157:464-9.
127. Yin D, Wang C, Singh V, et al. Delayed DNase-I administration but not gasdermin-D inhibition induces hemorrhagic transformation after transient focal cerebral ischemia in mice. Stroke. 2024;55:e297-9.
128. Allonen J, Nieminen MS, Lokki M, et al. Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol. 2012;35:E22-7.
129. Brown R, Lewsey J, Wild S, Logue J, Welsh P. Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. BMJ Open. 2021;11:e054893.
130. Kim MC, Cho JY, Jeong HC, et al. Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction. Am J Cardiol. 2015;115:1-7.
131. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335-45.
132. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229-43.
133. Milusev A, Rösch Y, Kuster Y, et al. Dissolving porcine and human microthrombi by short exposure to microdoses of alteplase in an in vitro model of microvascular obstruction. Sci Rep. 2025;15:18114.
134. Mehta SR, Pinilla-Echeverri N, Tiong D, et al. Intracoronary low-dose recombinant tissue plasminogen activator in primary PCI for ST-segment elevation myocardial infarction and large thrombus burden: a randomized trial. J Am Coll Cardiol. 2026;87:238-48.
135. Mccartney PJ, Eteiba H, Maznyczka AM, et al. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial. JAMA. 2019;321:56.
136. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379-87.
137. Ruze A, Chen B, Liu F, et al. Macrophage migration inhibitory factor plays an essential role in ischemic preconditioning-mediated cardioprotection. Clin Sci. 2019;133:665-80.
138. Kim EK, Hahn J, Song YB, et al. Effect of ischemic postconditioning on myocardial salvage in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the POST randomized trial. Int J Cardiovasc Imaging. 2015;31:629-37.
139. Sluijter JPG, Davidson SM, Boulanger CM, et al. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: position paper from the working group on cellular biology of the heart of the European Society of Cardiology. Cardiovasc Res. 2018;114:19-34.
140. White SK, Frohlich GM, Sado DM, et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2015;8:178-88.
141. Haller PM, Vargas KG, Haller MC, et al. Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials. Eur Heart J Acute Cardiovasc Care. 2018;9:82-92.
142. Eitel I, Stiermaier T, Rommel KP, et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur Heart J. 2015;36:3049-57.
143. Francis R, Chong J, Ramlall M, et al. Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Basic Res Cardiol. 2021;116:59.
144. Jovanović A. Cardioprotective signaling: outline and future directions. Biomedicines. 2025;13:2973.
146. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-826.
147. Rao SV, O’donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771-862.
